AEGERION PHARMACEUTICALS, INC. AND AMRYT PHARMA PLC PLAN FUNDING AGREEMENTPlan Funding Agreement • May 21st, 2019 • Novelion Therapeutics Inc. • Pharmaceutical preparations • New York
THIS PLAN FUNDING AGREEMENT (as it may be amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is made as of May 20, 2019, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Amryt Pharma plc, a company incorporated in England and Wales with the registered number 05316808 and registered address at Dept 920a 196 High Road, Wood Green, London, England, N22 8HH (the “Plan Investor” and, together with the Company, the “Parties” and each a “Party”). Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in Article I hereof.
RESTRUCTURING SUPPORT AGREEMENTRestructuring Support Agreement • May 21st, 2019 • Novelion Therapeutics Inc. • Pharmaceutical preparations • New York
This DEBTOR-IN-POSSESSION CREDIT AGREEMENT (this “Agreement”) is entered into as of May 20, 2019 among AEGERION PHARMACEUTICALS, INC., a Delaware corporation and a debtor and debtor-in-possession under Chapter 11 of the Bankruptcy Code (as hereinafter defined) (the “Borrower”), each Lender (as hereinafter defined) from time to time party hereto and CANTOR FITZGERALD SECURITIES, as administrative agent and collateral agent for the Lenders (in such capacities, together with any successor administrative agent and collateral agent, the “Administrative Agent”).
AMENDMENT TO SHARED SERVICES AGREEMENTSShared Services Agreements • May 21st, 2019 • Novelion Therapeutics Inc. • Pharmaceutical preparations
This Amendment to Shared Services Agreements (the “Amendment”), dated as of May 20, 2019, is entered into by and between Novelion Therapeutics Inc., a company incorporated under the laws of British Columbia (“Novelion”), Novelion Services USA, Inc., a Delaware corporation (“NSU”), and Aegerion Pharmaceuticals, Inc., a Delaware Corporation (“Aegerion”).
